Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 5/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20035000 | 0.84 | CYP3A4 (0.38) | ALDH1A1HPGDCYP3A4MAPK1KDM4E | |
| SCHEMBL312677 | 0.80 | ALDH1A1 (0.65) | ALDH1A1HPGDCYP3A4MAPK1KDM4E | |
| SCHEMBL29976235 | 0.80 | ALDH1A1 (0.65) | ALDH1A1HPGDCYP3A4MAPK1KDM4E | |
| SCHEMBL18177030 | 0.80 | MAPT (0.51) | ALDH1A1HPGDMAPK1KDM4EGAA | |
| Hydrochloric Acid SCHEMBL354001 | 0.79 | ALDH1A1 (0.62) | ALDH1A1HPGDCYP3A4MAPK1KDM4E | |
| Hydrochloric Acid SCHEMBL30735974 | 0.79 | ALDH1A1 (0.62) | ALDH1A1HPGDCYP3A4MAPK1KDM4E | |
| SCHEMBL16856324 | 0.79 | ALDH1A1 (0.58) | ALDH1A1HPGDCYP3A4MAPK1KDM4E | |
| SCHEMBL18823988 | 0.76 | KDM4E (0.57) | ALDH1A1CYP3A4KDM4EMAPTMAOB | |
| SCHEMBL28685254 | 0.75 | NR4A1 (0.56) | ALDH1A1HPGDCYP3A4MAPK1KDM4E | |
| SCHEMBL20214924 | 0.75 | ALDH1A1 (0.45) | ALDH1A1HPGDCYP3A4MAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230053449-A1 | DC-SIGN ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20220162308-A1 | ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-26 | — | — | US | disclosed |
| US-20210346387-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | NOVARTIS AG (CH) | 2021-11-11 | — | — | US | disclosed |
| US-20210228731-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2021-07-29 | — | — | US | disclosed |
| US-10973826-B2 | Antibody conjugates comprising toll-like receptor agonist | NOVARTIS AG (CH) | 2021-04-13 | — | — | US | disclosed |
| US-10787480-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2020-09-29 | — | — | US | disclosed |
| US-20200164084-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST AND COMBINATION THERAPIES | NOVARTIS AG (CH) | 2020-05-28 | — | — | US | disclosed |
| US-10392421-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2019-08-27 | — | — | US | disclosed |
| US-20190194315-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2019-06-27 | — | — | US | disclosed |
| US-10280139-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2019-05-07 | — | — | US | disclosed |
| US-9884817-B2 | Auristatin derivatives and conjugates thereof | NOVARTIS AG (CH) | 2018-02-06 | — | — | US | disclosed |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-12-14 | — | — | US | disclosed |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| US-20170121421-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| US-20170121421-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| WO-2016071856-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS AG (CH) | 2016-05-12 | — | — | WO | disclosed |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787480-B2 | Cytotoxic peptides and conjugates thereof | CD47, NGLY1, VIP | ALDH1A1 3311/4885HPGD 3718/4885CYP3A4 4571/4885 |
| US-20190194315-A1 | ANTIBODY DRUG CONJUGATES | EPCAM, CDH1, VIM | ALDH1A1 1376/4885HPGD 3765/4885CYP3A4 3789/4885 |
| US-20170121421-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | TLR3, TLR2, TLR9 | ALDH1A1 3021/4885HPGD 3267/4885CYP3A4 4599/4885 |
| US-10392421-B2 | Cytotoxic peptides and conjugates thereof | CD47, NGLY1, VIP | ALDH1A1 3311/4885HPGD 3718/4885CYP3A4 4571/4885 |
| US-20230053449-A1 | DC-SIGN ANTIBODY DRUG CONJUGATES | DCUN1D4, CD14, DCUN1D3 | ALDH1A1 2550/4885HPGD 3990/4885CYP3A4 3717/4885 |
| US-20210228731-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | BCR, ABL1, CD47 | ALDH1A1 167/4885HPGD 3832/4885CYP3A4 1926/4885 |
| US-20210346387-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | TLR3, TLR2, TLR9 | ALDH1A1 3021/4885HPGD 3267/4885CYP3A4 4599/4885 |
| US-20170355731-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | ALDH1A1 3212/4885HPGD 3861/4885CYP3A4 4698/4885 |
| US-10973826-B2 | Antibody conjugates comprising toll-like receptor agonist | TLR3, TLR2, TLR9 | ALDH1A1 3021/4885HPGD 3267/4885CYP3A4 4599/4885 |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, NGLY1, VIP | ALDH1A1 3311/4885HPGD 3718/4885CYP3A4 4571/4885 |
| US-20170121282-A1 | AURISTATIN DERIVATIVES AND CONJUGATES THEREOF | AURKC, AURKA, AURKB | ALDH1A1 1924/4885HPGD 4087/4885CYP3A4 4160/4885 |
| US-20220162308-A1 | ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | ITGB8, ITGA8, CD4 | ALDH1A1 1567/4885HPGD 3490/4885CYP3A4 1338/4885 |
| US-20200164084-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST AND COMBINATION THERAPIES | TLR3, TLR2, TLR9 | ALDH1A1 2626/4885HPGD 3705/4885CYP3A4 4718/4885 |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | ALDH1A1 1165/4885HPGD 4633/4885CYP3A4 2585/4885 |
| US-10280139-B2 | Cytotoxic peptides and conjugates thereof | CD47, MKI67, NGLY1 | ALDH1A1 3229/4885HPGD 3441/4885CYP3A4 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.